Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
Other

Tempramed launches Vivi Cap Smart

By The Northwire Desk — AI Analysis Dec 26, 2025 · 04:24 VIVI · 0.88 Tempramed Technologies Ltd
VIVI · Price

Executive Summary

  • Tempramed Technologies Ltd. has launched "Vivi Cap Smart," a new digital health product that expands its existing portfolio of passive temperature protection devices.
  • The new device integrates proprietary thermal insulation technology with digital functionality to help patients manage chronic conditions, specifically focusing on insulin and GLP-1 pen adherence.
  • This launch marks a strategic shift toward a "whole-patient platform" combining physical device innovation with digital tools for medication tracking and data sharing.

Key Details

  • Product Name: Vivi Cap Smart (an advanced evolution of the flagship Vivi Cap).
  • Core Functionality: Combines passive temperature protection for insulin/GLP-1 pens with digital health features.
  • Digital Features:
    • Automatically tracks injection timing.
    • Maintains an accurate log of insulin usage via an optional connected mobile application.
    • Displays elapsed time since the last injection directly on the device.
    • Records user-entered dose information.
  • Data Capabilities:
    • Data can be stored, tracked, and shared with healthcare providers.
    • Supports collaboration with caregivers, healthcare professionals, and corporations.
    • Enables data export for connected health and artificial intelligence models.
  • Strategic Context: Represents a transition toward a broader platform addressing daily care challenges for individuals managing chronic illnesses, aiming to reduce wasted medication and negative patient outcomes.
  • CEO Commentary: Ron Nagar, CEO, highlighted the move to address "everyday challenges of remembering and managing important injections" and extending proprietary technology to ease the burden of long-term care.

Notable Quotes

  • "Living with a chronic condition requires constant attention and decision making... With Vivi Cap Smart, we are extending our proprietary technology to address not only medication protection, but also the everyday challenges of remembering and managing important injections." — Ron Nagar, CEO
Read the original news release →

More from Tempramed Technologies Ltd

Jun 30, 2026 · 03:06

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

M&A / Property Jun 26, 2026 · 16:11

Pioneering passive thermal protection for temperature-sensitive injectables amid aggressive global distribution expansion.

M&A / Property Jun 04, 2026 · 07:01

TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

Other May 22, 2026 · 11:58

TempraMed Technologies Ltd.

Other May 14, 2026 · 03:01

Indian patent adds IP depth but revenue-sharing financing signals cash crunch

Financings Apr 07, 2026 · 07:01

Brazilian patent bolsters TempraMed’s IP moat ahead of VIVI Box launch.

M&A / Property